Information Provided By:
Fly News Breaks for June 20, 2018
Jun 20, 2018 | 07:24 EDT
Cantor Fitzgerald analyst Mara Goldstein believes Array BioPharma's combination of binimetinib/encorafenib has the "potential to be best-in-class and take a market-leader position." The FDA action date is June 30. Further, the analyst sees opportunity in BRAF+ CRC based on the safety lead-in portion of the Beacon study, which she believes could expand the potential market, with updated results to be presented on June 23. Goldstein thinks Array shares "could have further room to advance" and keeps an Overweight rating on the name with a $24 price target.
News For ARRY From the Last 2 Days
There are no results for your query ARRY
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.